Skip to main content

Humanin vs CJC-1295

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Humanin

Humanin is a mitochondrial-derived peptide with potent cytoprotective effects. Discovered in 2001, it has shown promise in protecting against age-related diseases including Alzheimer's, cardiovascular disease, and diabetes.

Full details →

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.

Full details →

Side-by-Side Comparison

AspectHumaninCJC-1295
MechanismBinds to IGFBP-3 and BAX, inhibiting apoptosis. Activates STAT3 signaling and enhances cellular survival under stress. Protects mitochondrial function and reduces oxidative stress.CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly.
Typical DosageResearch protocols vary widely. Studies have used doses from micrograms to milligrams depending on the analog and route. HNG (S14G-Humanin) is a more potent analog.CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily.
AdministrationSubcutaneous or intraperitoneal injection in research. Various analogs exist with different potencies and stabilities.Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted.
Side EffectsLimited human data. Generally well-tolerated in animal studies. May affect glucose metabolism.Water retention, tingling in extremities, potential increase in cortisol and prolactin levels.
Best For

Key Differences

Detailed Analysis

CJC-1295 and Humanin are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose CJC-1295 for Muscle Growth, Fat Loss, Sleep Quality. Choose Humanin for Cognitive Performance, Anti-Aging & Longevity.

Ready to Learn More?